Hwail Pharmaceutical Co.Ltd (061250) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hwail Pharmaceutical Co.Ltd (061250) has a cash flow conversion efficiency ratio of 0.033x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩6.82 Billion ≈ $4.62 Million USD) by net assets (₩207.86 Billion ≈ $140.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Hwail Pharmaceutical Co.Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Hwail Pharmaceutical Co.Ltd - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Hwail Pharmaceutical Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hwail Pharmaceutical Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hwail Pharmaceutical Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bank Mestika Dharma Tbk
JK:BBMD
|
0.018x |
|
JuneYao Dairy Co Ltd
SHG:605388
|
0.026x |
|
UPC Technology Corp
TW:1313
|
-0.018x |
|
Xiamen Savings Environmental
SHE:300056
|
-0.102x |
|
Axiomtek Co Ltd
TWO:3088
|
0.035x |
|
Fujian Green Pine Co Ltd
SHE:300132
|
-0.038x |
|
Shanghai Huide Science & Technology Co Ltd
SHG:603192
|
0.032x |
|
Hearts and Minds Investments Ltd
AU:HM1
|
-0.012x |
Annual Cash Flow Conversion Efficiency for Hwail Pharmaceutical Co.Ltd (2011–2024)
The table below shows the annual cash flow conversion efficiency of Hwail Pharmaceutical Co.Ltd from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Hwail Pharmaceutical Co.Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩203.42 Billion ≈ $137.85 Million |
₩11.63 Billion ≈ $7.88 Million |
0.057x | +42.04% |
| 2023-12-31 | ₩174.45 Billion ≈ $118.22 Million |
₩7.02 Billion ≈ $4.76 Million |
0.040x | +3126.94% |
| 2022-12-31 | ₩175.57 Billion ≈ $118.98 Million |
₩-233.56 Million ≈ $-158.28K |
-0.001x | -101.20% |
| 2021-12-31 | ₩181.66 Billion ≈ $123.11 Million |
₩20.09 Billion ≈ $13.61 Million |
0.111x | +8700.50% |
| 2020-12-31 | ₩156.86 Billion ≈ $106.30 Million |
₩-201.69 Million ≈ $-136.68K |
-0.001x | -104.16% |
| 2019-12-31 | ₩119.43 Billion ≈ $80.94 Million |
₩3.69 Billion ≈ $2.50 Million |
0.031x | -56.33% |
| 2018-12-31 | ₩101.25 Billion ≈ $68.61 Million |
₩7.17 Billion ≈ $4.86 Million |
0.071x | -16.62% |
| 2017-12-31 | ₩98.18 Billion ≈ $66.53 Million |
₩8.34 Billion ≈ $5.65 Million |
0.085x | -11.50% |
| 2016-12-31 | ₩99.86 Billion ≈ $67.67 Million |
₩9.58 Billion ≈ $6.49 Million |
0.096x | +237.50% |
| 2015-12-31 | ₩98.94 Billion ≈ $67.05 Million |
₩-6.90 Billion ≈ $-4.68 Million |
-0.070x | -123.28% |
| 2014-12-31 | ₩89.07 Billion ≈ $60.36 Million |
₩-2.78 Billion ≈ $-1.89 Million |
-0.031x | -138.69% |
| 2013-12-31 | ₩86.31 Billion ≈ $58.49 Million |
₩6.97 Billion ≈ $4.72 Million |
0.081x | +561.06% |
| 2012-12-31 | ₩82.22 Billion ≈ $55.72 Million |
₩1.00 Billion ≈ $680.89K |
0.012x | -89.19% |
| 2011-12-31 | ₩69.49 Billion ≈ $47.09 Million |
₩7.86 Billion ≈ $5.32 Million |
0.113x | -- |
About Hwail Pharmaceutical Co.Ltd
Hwail Pharmaceutical Co.,Ltd. develops pharmaceutical raw materials in South Korea. It provides raw drug products, finished drug products, and functional health food raw material business. The company was founded in 1974 and is headquartered in Seongnam-si, South Korea.